Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 ...

Kille Knobel complements shows with minimalist yet impactful lighting design LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- ...

CHARLOTTESVILLE, VA / ACCESSWIRE / November 11, 2024 / Pearl Certification, a national leader in home performance ...

CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: Guggenheim's Inaugural Healthcare ...

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 trial of V940 (mRNA-4157). V940 is an investigational ...

It sounds like Pearl Abyss’ next game will live up to the hype. More details have emerged about Pearl Abyss’ upcoming open world game Crimson Desert. Earlier this week, we reported on how the ...

The Food and Drug Administration approved a handful of updated COVID-19 vaccinations for the 2024-25 fall and winter seasons, including inoculations from Pfizer and Moderna, in late August.

Abrysvo is now approved for adults aged 18-59 years at increased risk for RSV due to chronic conditions, expanding its previous indications. The FDA's decision is based on a phase 3 trial showing ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

Tyler Van Buren’s rating is based on several factors influencing Moderna’s financial outlook. The analyst has adjusted the company’s expense projections downward, reflecting a more ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine ...

To date, no vaccines that protect NoV have been licensed. Credit: Novikov Aleksey via Shutterstock. At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, ...